MedPath
FDA Approval

Ibandronate Sodium

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
AuroMedics Pharma LLC
DUNS: 968961354
Effective Date
March 28, 2022
Labeling Type
Human Prescription Drug Label
Ibandronate(3 mg in 3 mL)

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Aurobindo Pharma Limited

AuroMedics Pharma LLC

918917626

Eugia Pharma Specialities Limited

AuroMedics Pharma LLC

650498244

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ibandronate Sodium

Product Details

NDC Product Code
55150-191
Application Number
ANDA205332
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
May 5, 2022
Code: J12U072QL0Class: ACTIMQuantity: 3 mg in 3 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath